title: Selective intraarterial chemoradiation therapy for oropharyngeal carcinoma with high-dose cisplatin.
abstract: OBJECTIVE
  Cisplatin has shown a high tumor response rate among head and neck carcinomas, and the tumor response is related to the cisplatin dosage. The purpose of this study was to evaluate the efficacy and toxicity of selective intraarterial chemoradiation therapy for oropharyngeal carcinomas with high-dose cisplatin.
  
  
  METHODS
  This retrospective study consisted of 21 patients with oropharyngeal carcinoma, stages II-IVB, in whom intraarterial chemoradiation therapy was performed between 2000 and 2008. All patients were given two courses of selective intraarterial infusions of cisplatin (300 mg/m(2)), systemic chemotherapy with 5-fluorouracil, and simultaneous radiation therapy (58-61 Gy/30 fractions), with a 1-week rest period.
  
  
  RESULTS
  The 2-year overall survival rate of the 15 patients who completed the therapeutic regimen was 71.3%. The 2-year locoregional control rate and disease-free survival rate were 95.0% and 67.7%, respectively.
  
  
  CONCLUSIONS
  Selective intraarterial high-dose cisplatin chemotherapy with concomitant radiation therapy shows results similar to those of original methods in terms of survival and locoregional control with a reduction in the number of procedure times.
authors.affiliation: Department of Radiology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
authors.forename: Ryota
authors.initials: R
authors.lastname: Nishio
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Saito
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ito
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Yoshida
authors.forename: Koichi
authors.initials: K
authors.lastname: Kitamura
authors.forename: Akira
authors.initials: A
authors.lastname: Shimizu
authors.forename: Naoto
authors.initials: N
authors.lastname: Kanesaka
authors.forename: Ryuji
authors.initials: R
authors.lastname: Mikami
authors.forename: Daisuke
authors.initials: D
authors.lastname: Hasegawa
authors.forename: Mamoru
authors.initials: M
authors.lastname: Suzuki
authors.forename: Koichi
authors.initials: K
authors.lastname: Tokuuye
mesh_terms: D000328:Adult; D000368:Aged; D000792:Angiography; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003287:Contrast Media; D019583:Dose Fractionation, Radiation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D007472:Iohexol; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D007472:Iohexol; D002945:Cisplatin; D005472:Fluorouracil